Opinion|Videos|October 7, 2024
Vitiligo Treatment Paradigms: Clinician Experiences with Topical Ruxolitinib and Access Challenges
Author(s)Terry Faleye, MPAS, PA-C
Panelists discuss how their clinical experiences with topical ruxolitinib are shaping new treatment paradigms for vitiligo, while also addressing challenges related to medication access.
Advertisement
Episodes in this series
Advertisement
Related to this article
The FDA clearance allows Edesa to expand an ongoing placebo-controlled study of the CXCL10 antibody EB06 to US sites, with topline data expected in the fourth quarter of 2027.
Dermatology clinicians at a Case-Based Roundtable in Austin, Texas, discussed real-world strategies for sequencing topical therapy, phototherapy, and ruxolitinib cream across pediatric and adult vitiligo cases.
Advertisement
Advertisement
Trending on Dermatology Times
1
Bitopertin Meets All End Points in Phase 3 APOLLO Trial for EPP
2
Dupilumab Associated With Lower Atopic March Risk in Pediatric Atopic Dermatitis
3
Social Media Mythbusters: Can Castor Oil Really Grow Hair?
4
EADV 2026 Atopic Dermatitis Highlights: Tilrekimig, RAC2 Inhibition, and Level Up Data
5